Safety of vaginal estrogen in breast cancer survivors: Current evidence on systemic absorption and oncologic outcomes
Maturitas · 2026
DOI: 10.1016/j.maturitas.2026.108914 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Maturitas, 2026. Verfasst von Laura Baquedano Mainar und 7 weiteren Autor:innen. Beteiligte Einrichtung: Gynaecology Department, Miguel Servet University Hospital, Institute for Health Research Aragón (IIS Aragón), P.° de Isabel la Católica, 1-3, 50009, …. Hauptthemen laut MEDLINE: Breast Neoplasms, Estrogens, Estrogen Replacement Therapy. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: Gedeon Richter.
Abstract (Originalsprache)
Vaginal estrogen is widely used to manage the genitourinary syndrome of menopause. However, its use by breast cancer survivors remains controversial, since some labeling indicates that it may increase the risk of recurrence, based on the known risks of systemic hormone therapy. This review synthesizes current evidence on breast cancer incidence and the use of vaginal estrogen in postmenopausal women, and its systemic absorption, as well as recurrence, mortality, and comparative data among vaginal estrogen formulations in breast cancer survivors, including those receiving aromatase inhibitors. Our findings show that vaginal estrogen results in minimal systemic absorption, and no demonstrated increase in the incidence of breast cancer, its recurrence, or mortality from breast cancer. In breast cancer survivors treated with aromatase inhibitors, vaginal estrogen has not been associated with increased mortality, although evidence on its effect on recurrence remains controversial and the issue warrants further investigation. The absence of head-to-head comparisons of different formulations of vaginal estrogen in breast cancer survivors emphasizes the need for comparative studies to guide individualized treatment strategies. Recent updates from the US Food and Drug Administration, which removed boxed warnings related to breast cancer and acknowledged that vaginal estrogens have a safety profile that is distinct from that of systemic hormone therapy, reinforce our findings and represent an important step toward evidence-based regulation. Building on these regulatory advances, the increasing diagnosis of breast cancer in younger women and the prolonged burden of genitourinary syndrome of menopause underscore the need to translate this evidence into clinical practice by strengthening clinical confidence and supporting individualized, patient-centered decision-making for breast cancer survivors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gynaecology Department, Miguel Servet University Hospital, Institute for Health Research Aragón (IIS Aragón), P.° de Isabel la Católica, 1-3, 50009, Zaragoza, Spain. Electronic address: lbaquedanome@hotmail.com.
- Gynaecology Department, Reina Sofía University Hospital, Avenida Menéndez Pidal s/n, 14004, Córdoba, Spain. Electronic address: doctora1983@gmail.com.
- Gynaecology Department, Hospital Valme, Carretera de Cádiz s/n, 41014, Sevilla, Spain. Electronic address: iglesiasbravo@yahoo.es.
- Hospital Universitario Cruces, Plaza de Cruces 12, 48903, Baracaldo, Vizcaya, Spain. Electronic address: doctorborjaotero@gmail.com.
- Department of Obstetrics and Gynaecology, Hospital Universitario San Agustín, Camino de Heros, 6, 33401, Avilés, Spain. Electronic address: irisporcel.4@gmail.com.
- Alta Medical Services, Ronda Sant Pere, 52, 08010, Barcelona, Spain. Electronic address: celiatorresvilanova3@gmail.com.
Förderung
- Gedeon Richter
Zitieren
APA
Mainar, L. B., Nieto-Pascual, L., Bravo, E. I., García-Ramos, B. O., Llaneza, I. P., Vilanova, C. T., Lloret, A. M., & Alsina, J. C. (2026). Safety of vaginal estrogen in breast cancer survivors: Current evidence on systemic absorption and oncologic outcomes. Maturitas. https://doi.org/10.1016/j.maturitas.2026.108914
Vancouver
Mainar LB, Nieto-Pascual L, Bravo EI, García-Ramos BO, Llaneza IP, Vilanova CT, et al. Safety of vaginal estrogen in breast cancer survivors: Current evidence on systemic absorption and oncologic outcomes. Maturitas. 2026. doi:10.1016/j.maturitas.2026.108914
BibTeX
@article{Mainar2026,
author = {Mainar, Laura Baquedano and Nieto-Pascual, Laura and Bravo, Eva Iglesias and García-Ramos, Borja Otero and Llaneza, Iris Porcel and Vilanova, Cèlia Torres and Lloret, Anna Muñoz and Alsina, Joaquim Calaf},
title = {Safety of vaginal estrogen in breast cancer survivors: Current evidence on systemic absorption and oncologic outcomes},
journal = {Maturitas},
year = {2026},
doi = {10.1016/j.maturitas.2026.108914}
}
EUVIMED